Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Makes Strides with Patented DehydraTECH™ Drug Delivery Platform

October 23, 2019 12:08:29
  • Lexaria Bioscience Corp. continues to make progress in the patenting and development of its DehydraTECH™ platform
  • Lexaria developed the patented DehydraTECH™ drug delivery platform as a safer alternative to inhalation of nicotine or cannabinoids
  • DehydraTECH™ has been shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has levered innovation, research and development into operations in four market verticals: cannabis, hemp, nicotine, and pharmaceuticals. Lexaria already introduced the DehydraTECH™ drug delivery platform into commercial use and has a second-generation delivery platform ready for launch in 2020. Lexaria is the only company in the world to receive a patent for this improved oral delivery of all non-psychoactive cannabinoids including CBD. In fact, the company has 16 patents already granted along with more than 60 patents that are pending worldwide (http://cnw.fm/Bnsc5).

Lexaria has cannabinoid licensing agreements with various companies in North America. The popularity of cannabinoid products such as CBD is likely to increase in the future and the U.S. cannabis market alone is projected to grow substantially in the future (http://cnw.fm/3F3xc). Lexaria’s delivery technology is already being used by the CBD/hemp industry and could experience radical growth in step with the industry.

The DehydraTECH™ drug delivery platform is an innovative technology that was developed as a way to safely and effectively deliver substances both to the bloodstream and to the brain via the oral ingestion route. Substances such as nicotine and cannabidiol are historically inhaled, a choice that is harmful to health compared with non-inhalation methods.

Inhalation can be problematic and dangerous especially for individuals who may have other medical issues. The DehydraTECH™ drug delivery platform can be used to deliver substances in edible or in beverage form, and in capsules, pills, syrups and more. Brands in both Canada and the USA have licensed DehydraTECH™ to make their CBD and cannabis beverages best-in-class.

Not only is ingestion a much safer form of drug delivery, but DehydraTECH™ also delivers the active ingredient of the substance at a rate that is up to five to ten times faster compared with traditional edible products. A 2018 European clinical study demonstrated that 317 percent more CBD was delivered within half an hour when compared with a positive control of equal strength (http://cnw.fm/2T9z2). The substance being delivered is also rapidly absorbed which means that people can achieve the effect they are looking for more quickly than was previously the case with edibles. For people looking for quick relief of pain, DehydraTECH is a blessing.

Many human receptor cells are clustered primarily in the brain or central nervous system, so in order to treat conditions, drugs need to effectively reach these areas of the body which has historically been difficult to do. Research studies done with animals have demonstrated delivery of 1,937 percent more cannabidiol (and over 500 percent more nicotine) into the brain tissue after 8 hours when using the enhanced DehydraTECH™ when compared with using generic industry MCT coconut-oil formulations. Greater effectiveness can mean safer, lower doses. The increased bioavailability and speed of onset are important factors when delivering substances to the brain and is especially important for people who need rapid relief from unpleasant and debilitating symptoms.

Studies done in the laboratory have also shown dramatically improved oral nicotine delivery using the DehydraTECH™ platform. Lexaria has partnered with one of the world’s largest tobacco companies to help fund the research and development of DehydraTECH™ as it relates to nicotine delivery (http://cnw.fm/j6HFy).

A big advantage of the DehydraTECH™ drug delivery platform when it comes to nicotine is that the delivery is fast when compared with other oral forms of nicotine – such as nicotine lozenges or nicotine gum. Users are less likely to get frustrated if they can feel the effects of the nicotine faster when taken in through the oral route. Lower-risk technologies are needed when it comes to nicotine, which is something that the government has recognized since smoking is known to be deadly. Therefore, technology developed to reduce health risks is highly beneficial.

DehydraTECH™ drug delivery platform has applications for the pharmaceutical industry and could be used to deliver fat-soluble drugs. It also could be used to deliver NSAID medications such as ibuprofen or acetylsalicylic acid. DehydraTECH™ has the advantage of allowing substances to bypass first phase liver metabolism.

The technology uses GRAS (Generally Recognized As Safe) food ingredients and further advantages are that the technology removes the bitter flavors and odors of many drugs. This is beneficial because artificial sweeteners do not need to be added to the product to enhance its taste and make it palatable. Sugar may be an issue, especially for people who have diabetes, thus a sugar-free product would be a healthier option.

Lexaria was recently granted two granted patents related to the treatment of heart disease, Alzheimer’s, Parkinson’s and schizophrenia. The treatment of these and other types of neurological disorders in particular has been problematic due to the blood-brain barrier – which makes it difficult for the brain to take up the needed medications. This barrier is formed by endothelial cells which function to prevent dangerous substances from passing into the brain from blood vessels, but the problem is that this also often stops helpful drugs from being able to enter the brain. The patented DehydraTECH™ drug delivery platform helps overcome this limitation to rapidly deliver essential medications to the brain.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office